Scarica l'app Stockscreener
106.14
0.07%
-0.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$106.21
Aprire:
$106.18
Volume 24 ore:
5.86M
Relative Volume:
0.80
Capitalizzazione di mercato:
$157.03B
Reddito:
$18.49B
Utile/perdita netta:
$2.51B
Rapporto P/E:
63.18
EPS:
1.68
Flusso di cassa netto:
$2.72B
1 W Prestazione:
+2.41%
1M Prestazione:
+1.77%
6M Prestazione:
+4.12%
1 anno Prestazione:
+42.93%
Intervallo 1D:
$105.94
$107.25
Intervallo di 1 settimana:
$103.01
$108.53
Portata 52W:
$71.88
$108.53
Boston Scientific Corp Stock (BSX) Company Profile
Nome
Boston Scientific Corp
Settore
Industria
Telefono
508-683-4000
Indirizzo
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Confronta BSX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
106.14 | 157.13B | 18.49B | 2.51B | 2.72B | 1.68 |
|
ABT
Abbott Laboratories
|
126.54 | 218.59B | 43.11B | 13.98B | 6.66B | 7.98 |
|
SYK
Stryker Corp
|
403.53 | 151.59B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
92.94 | 118.29B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
80.00 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-16 | Iniziato | Leerink Partners | Outperform |
| 2025-04-16 | Aggiornamento | Needham | Hold → Buy |
| 2025-01-10 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-10-18 | Downgrade | Needham | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-02-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-07-19 | Iniziato | Robert W. Baird | Outperform |
| 2023-06-30 | Iniziato | CL King | Buy |
| 2023-05-30 | Ripresa | Morgan Stanley | Overweight |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-12-22 | Iniziato | Mizuho | Neutral |
| 2022-12-20 | Ripresa | Citigroup | Buy |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-06 | Iniziato | Wolfe Research | Outperform |
| 2022-05-27 | Aggiornamento | Needham | Hold → Buy |
| 2022-04-13 | Ripresa | Truist | Buy |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-05-26 | Downgrade | Needham | Buy → Hold |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2020-09-17 | Iniziato | Truist | Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Peer Perform |
| 2020-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-01 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Buy |
| 2019-12-30 | Reiterato | Cowen | Outperform |
| 2019-12-19 | Downgrade | Needham | Strong Buy → Buy |
| 2019-09-05 | Ripresa | JP Morgan | Overweight |
| 2019-09-03 | Ripresa | Barclays | Overweight |
| 2019-05-13 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-11-28 | Iniziato | UBS | Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-10-02 | Reiterato | Morgan Stanley | Overweight |
| 2018-09-07 | Reiterato | Needham | Strong Buy |
| 2018-09-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2018-07-06 | Reiterato | Needham | Strong Buy |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-04-26 | Reiterato | Needham | Strong Buy |
Mostra tutto
Boston Scientific Corp Borsa (BSX) Ultime notizie
TD Cowen Reiterates a Buy Rating on Boston Scientific Corporation (BSX) - Insider Monkey
FSHPU seeks shareholder OK to cut extension fee to $60k/month, preserve GFT merger | BSX SEC FilingForm 144 - Stock Titan
Boston Scientific's (NYSE:BSX) investors will be pleased with their solid 173% return over the last five years - Yahoo.co
Boston Scientific Reports Strong Q2 2025 Results - The Globe and Mail
Boston Scientific (BSX) Target Price Raised by Raymond James | B - GuruFocus
Boston Scientific (BSX) Price Target Raised by Oppenheimer | BSX Stock News - GuruFocus
Is Boston Scientific Corporation stock overhyped or has real potentialSuperior stock growth - jammulinksnews.com
Boston Sci posts 117% U.S. PFA growth, halves tariff impact - BioWorld MedTech
Boston Scientific stock price target raised to $130 from $124 at Bernstein - Investing.com Canada
Boston Scientific (BSX) Price Target Increased by RBC Capital | - GuruFocus
BSX: Boston Scientific Sees Price Target Raised by Truist Securi - GuruFocus
Stocks making big moves yesterday: Power Integrations, Booz Allen Hamilton, Wendy's, SentinelOne, and Boston Scientific - Yahoo Finance
Boston Scientific (BSX) Price Target Raised by Baird Analyst | B - GuruFocus
Boston Scientific Corporation (NYSE:BSX) Q2 2025 Earnings Call Transcript - Insider Monkey
Boston Scientific stock price target raised to $140 from $130 at Mizuho - Investing.com
Boston Scientific (BSX) Price Target Increased by Baird | BSX Stock News - GuruFocus
Boston Scientific (BSX) Price Target Raised to $118 by Oppenheimer | BSX Stock News - GuruFocus
UBS Boosts Price Target for Boston Scientific (BSX) Amid Strong Performance | BSX Stock News - GuruFocus
Company News for Jul 24, 2025 - The Globe and Mail
Boston Scientific stock price target raised to $124 by Wells Fargo on PFA growth - Investing.com
Boston Scientific (BSX) Sees Price Target Boost from Barclays | - GuruFocus
Boston Scientific Corp (BSX) Q2 2025 Earnings Call Highlights: Surpassing Expectations with ... By GuruFocus - Investing.com Canada
Boston Scientific’s Strong Financial Performance and Positive Outlook Earns Buy Rating - TipRanks
Should You Buy or Sell Boston Scientific Stock Ahead of Its Upcoming Earnings? - Nasdaq
Why Boston Scientific (BSX) Stock Is Up Today - Yahoo Finance
Boston Scientific lifts 2025 outlook following 29% Q2 cardiovascular profit rise - Yahoo Finance
Boston Scientific Beats on Q2 Earnings, Raises 2025 View, Stock Up - The Globe and Mail
Boston Scientific stock price target raised to $120 by BofA Securities - Investing.com
Boston Scientific (BSX) Price Target Increased by BofA Analyst | - GuruFocus
Boston Scientific Presses Its Advantage in Pulsed Field Ablation - Morningstar
Boston Scientific halves expected tariff hit - MedTech Dive
Boston Scientific Lifts Outlook On Cardiovascular Revenue Growth - Finimize
Boston Scientific lifts annual profit forecast, sees smaller tariff impact - Reuters
Boston Scientific lifts annual profit forecast, sees smaller tariff impact By Reuters - Investing.com
Boston Scientific Reports Higher Profit Margins In Q2, Lifts Guidance - Benzinga
Boston Scientific stock hits all-time high at 107.76 USD - Investing.com
Boston Scientific stock hits all-time high at 107.76 USD By Investing.com - Investing.com UK
Earnings call transcript: Boston Scientific Q2 2025 beats expectations, stock rises - Investing.com
Boston Scientific lifts annual profit view on steady heart devices demand - Yahoo.co
Boston Scientific: Q2 Earnings Snapshot - CTPost
Boston Scientific (BSX) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
Boston Scientific increases full-year guidance after Q2 beats - MassDevice
Boston Scientific Q2 2025 Earnings Outperform Guidance with 22.8% Sales Growth 13.6% EPS Rise - AInvest
Boston Scientific Corp (BSX) Q2 2025 Earnings: EPS of $0.53 Beats Estimate, Revenue Surges to $5.061 Billion - GuruFocus
Boston Scientific Boosts FY25 OutlookUpdate - Nasdaq
Boston Scientific (BSX) Surpasses Q2 Earnings and Revenue Expectations - GuruFocus
Boston Scientific Q2 2025 slides: 22.8% sales growth fueled by Electrophysiology surge - Investing.com
Boston Scientific trumps top and bottom-line forecasts, issues upbeat 2025 guide - Investing.com
Boston Scientific earnings beat by $0.02, revenue topped estimates - Investing.com
Boston Scientific (NYSE:BSX) Reports Bullish Q2, Guides for Strong Sales Next Quarter - Yahoo Finance
Boston Scientific Q2 2025 Financial Results - TradingView
Boston Scientific Corp Azioni (BSX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.73%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):